LAS VEGAS, Feb. 27, 2018 /CNW/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations.
The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere.
GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids. GB Sciences will breed CBD into the genetics of the hemp plants and then analyze and optimize results.
Kevin Kuethe, COO GB Sciences, said: “This arrangement with the superb growers at the Colorado Hemp Project will give us the ability to manipulate genetics in a way that creates rare and beneficial plants, providing us with the necessary link between the research on the one hand and the realization of custom boutique hemp genetics on the other.”
“Wild” Bill Billings, co-founder of the Colorado Hemp Project with daughter Danielle, comments: “More than 25yrs in agriculture business has taught me that the fundamental of any good business is in its relationships with people. For us, it’s all about our relationship with the farmers. We are here to help them. We’ve persuaded these farmers to abandon money losing crops for hemp, a crop positioned to change their lives as well as livelihoods. We feel a kindred spirit in the visionary mission of GB Sciences and look forward to changing the face of the world together by educating more people about the magic of the hemp plant.”
John Poss, CEO & Chairman of the Board, concludes: “This is the first of many anticipated collaborations with the Colorado Hemp Project. We consider this a great step forward in developing cannabis genetics for hemp and are extremely pleased to be entering into this venture.”
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Tom Arcuragi, EVP, email@example.com
SOURCE GB Sciences, Inc.